Several biomarkers, including PD-1, PD-L1, tumor mutation burden (TMB), IFN-γ signature, and HPV factors, have been identified to evaluate the efficacy of immunotherapy in HNSC patients, but only PD-L1 is widely used in clinical practice, and the overall predictive effect is unsatisfactory [15]. Here, CD274 is linked to neoplasm.